

Basic NeuroEndovascular Training Course 3 (BNET Course)


BNET 3rd : Advanced Treatment Strategies for aneurysm (Flow diverter & disruptor)

일시 : 2024년 5월 11일(토)

장소 : 대웅제약본사 별관 베어홀 (지하1층)
(서울 강남구 봉은사로 114길 12)

주최 : 대한뇌혈관내치료의학회

주관 : 대한신경외과학연구재단



INVITATION ···

회원 여러분 안녕하십니까?

2024년 유례없는 의료파국 직전의 상황에서, 현 의료사태를 고려하여 BNET-1 (2024.03.16)과 BNET-2 (2024.04.20) 행사를 취소하였으나, 세 번째 course는 많은 전임의 및 Juior staff 선생님들이 신청 하시어 학회 수련교육 중요성을 감안, 개최하게 되었습니다.

BNET-3는 학회의 후반기 교육행사인 ANTE (Advanced Neuroendovascular Technique Education)에 앞서, Flow diverter 및 Flow disruptor를 강의 및 hands-on으로 접해 보는 좋은 기회가 될 것입니다.

대한민국 의료 파국을 막기 위하여 불철주야 진료에 힘쓰고 계시는 교수님들께 경의를 표합니다.

감사합니다.

2024년 5월 11일

대한뇌혈관내치료의학회 회 장 권순찬
부회장 박석규
총무이사 하성곤
교육수련이사 김영우, 박중철

PROGRAM

일시 : 2024년 5월 11일(토)





장소 : 대웅제약본사 별관 베어홀

08:30-08:50	Registration		
08:50-09:00	Course Introduction	김영우	KoNES 교육수련이사
	Welcome Address	권순찬	KoNES 회장
09:00-09:30	Flow diverter: devices review	박근영	연세대 신촌세브란스병원 07
09:30-10:00	Flow diverter: technique and complication	정영진	영남대병원 31
10:00-10:45	Flow distrupctor	정준호	연세대 강남세브란스병원 61
10:45-11:00	Break		
11:00-12:00	Hands-on		
12:00-13:00	Lunch		
13:00-	Closing & Photo time	하성곤	KoNES 총무이사

Flow diverter: devices review

박근영

연세대 신촌세브란스병원



2024 Basic NeuroEndovascular Training course-3

Overall review of flow diverter for the treatment of large or complex intracranial aneurysms

Keun Young PARK, MD. PhD.

Department of Neurosurgery
Severance Hospital, Yonsei University College of Medicine



Disclosures


- ✓ **Microvention: Proctorship**
- ✓ **Balt: Proctorship**
- ✓ **Stryker: Research grants**

Contents


- Introduction of Stent
- Introduction of FD
- Each Characteristic


Stent materials

- ✓ Nitinol: Nickel + Titanium
 - Shape-memory alloy; self-expanding
 - Superelasticity
- ✓ Co-Cr: Cobalt + Chrome
 - High wear resistance
 - Radiopaque
 - Balancing visibility and radial strength
- ✓ Radiopacity: Tantalum or Platinum



DFT (Drawn Filled Tubing)





Laser cutting vs Wire braiding

LASER cutting

✓ From Nitinol tube



- ✓ Less shortening
- ✓ More chronic outward force (COF)
- ✓ Lower Metal coverage

Neuroform Atlas, Enterprise, Acclino


Wire braiding

✓ From fine wires



- ✓ More shortening
- ✓ Less chronic outward force (COF)
- ✓ Higher metal coverage

LVIS, Accero, Flow Diverters



Concept of FD

Porosity: Ratio of metal free surface area in a stented vessel
Pore Density: Number of pores per unit surface area

DIAGRAM A




DIAGRAM B



Schematic showing equal porosity (50%) but different pore densities.
Diagram A has 16 times higher pore density than diagram B.


Concept of FD




Thrombus can be a main cause of proteolytic activities.

Concept of FD


In Animal study: "Organizing Thrombus & "Neointima"





Courtesy of Lee JY





Severance FD Protocol




M/40, Rt MCA dissection




BNET 3rd : Advanced Treatment Strategies for aneurysm (Flow diverter & disruptor)








6 months F/U



BNET 3rd : Advanced Treatment Strategies for aneurysm (Flow diverter & disruptor)









F/68, ICA-cavernous aneurysm, growing



1. Stent-assisted coiling
2. Proximal Occlusion
3. Trapping & EIAB
4. Covered stent
5. Flow diverter

F/68, ICA-cavernous aneurysm, growing







		Labeled diameters (mm)					5.25
		2.5	3.25	4.0	4.5	5.0	
Unconstrained diameter		2.7	3.7	4.2	4.7	5.2	
Recommended parent vessel diameter		2.0-2.5	>2.5-3.25	>3.25-4.0	>4.0-4.5	>4.5-5.0	
# of wires		48	64				
Length (mm)	12						
	15						
	17						
	20						
	25						
	30						
	40						
50							

Incorporating artery or perforators

LT M1 fusiform aneurysm incorporating LSA





FRED, Microvention



FRED/FRED Jr.

- ✓ Nitinol+Tantalum
- ✓ Flare end
- ✓ FRED: available in 027' MC
 - *Dual layer
 - Outer 16: higher radial force
 - Inner 48: better flow diversion
- ✓ FRED Jr. : available in 021' MC
 - *Dual layer
 - Outer 16: higher radial force
 - Inner 36: better flow diversion

FRED X

- ✓ Nitinol+Tantalum
- ✓ Flare end
- ✓ X-technology

FRED & FRED Jr.



FRED X



Delivery wire tip	FRED X 27 has a 5mm distal delivery wire tip FRED X 21 has a delivery wire set in the center of device
Immediate withdrawal of pusher wire upon full deployment	No need to re-cross deployed FRED X Device with the microcatheter
Smooth delivery with low delivery forces ¹	Allows for easier tracking through tortuous anatomies

	Diameter	Working Length / Total Length
FRED X 21	2.5mm	8 / 13
		13 / 18
		20 / 25
		26 / 30
	3.0mm	9 / 13
		14 / 19
FRED X 27	3.5mm	21 / 27
		27 / 32
		7 / 13
		11 / 17
	4.0mm	16 / 22
		24 / 31
		36 / 40
		7 / 13
	4.5mm	12 / 18
		17 / 23
		26 / 32
		38 / 44
	5.0mm	8 / 15
		13 / 20
		18 / 25
		28 / 34
	5.5mm	39 / 45
		9 / 15
	5.5mm	14 / 21
		19 / 26
	5.5mm	29 / 36
		14 / 22
	5.5mm	26 / 32



Derivo, Acandis

Derivo/Derivo mini

- ✓ DFT (Nitinol)
- ✓ Closed end
- ✓ BlueXide surface finishing
- ✓ Derivo: available in 027' MC
- ✓ Derivo mini : available in 021' MC

Derivo II

Low profile

Diameter [mm]	2.5	3.0	3.5	3.5	4.0	4.5	5.0	5.5	6.0
Length [mm]	10, 15, 20, 25*			30, 40	15, 20, 25, 30, 40		15, 20, 25, 30, 40, 50		
Delivery catheter	0.017"			0.027"					
Inner diameter									
Outer diameter	2F			3F					

BNET 3rd : Advanced Treatment Strategies for aneurysm (Flow diverter & disruptor)

	DERIVO® 2										DERIVO® mini			DERIVO®				
Diameter [mm]	2.5	3.0	3.5	4.0	4.5	5.0	5.5	6.0	7.0	8.0	2.5	3.0	3.5	3.5	4.0, 4.5, 5.0, 5.5, 6.0			
Amount of wires (in total)	48					52					28		32		36		48	
Wire diameter [mm]	0.030 mm 24 wires		0.038 mm 24 wires		0.042 mm 26 wires		0.046 mm 32 wires		0.035 mm 20 wires		0.035 mm 24 wires		0.035 mm 34 wires		0.035 mm 46 wires			
									0.043 mm 8 double wires		0.043 mm 8 double wires		0.043 mm 2 double wires		0.043 mm 2 double wires			
Braiding angle middle segment	70°		75°					Not available in Korea			70°			75°				
Porosity																		
upper IU [%]	62	63	66	64	67	64	67	69	64	65	62	67	77	68	63-72			
lower IU [%]	66	72	77	74	77	75	77	79	75	76	65	73	81	77	73-81			
X-ray Visibility	- Platinum Nitinol composite wires with higher platinum rate in wire core (30%) - Transport wire tip										- Platinum Nitinol composite wires (10% platinum) - Double wires (20% platinum) - Transport wire tip - Three platinum Iridium markers on each end							
Transport wire	1 tip configuration 2F: 10-25mm with short straight tip 3F: 15/20/25/30mm with j-tip and 40/50 mm w/o tip 4F: 20/25/30mm with j-tip and 40/50 mm w/o tip										2 tip configurations for 20/25mm with j-tip and w/o tip			1 tip configuration 15/20/25/30 mm with j-tip and 40/50 mm w/o tip				
Material											NiTi							
BlueXide®											Yes							
Resheatable											Yes							

제조사	Medtronic	Stryker	Microvention	Acandis
제품명	Pipeline Vantage	Surpass Elite	FRED X	Derivo II
재질	DFT (Co-Cr)	Co-Cr & Pt/tungsten	Nitinol/Tantalum	DFT (Nitinol)
Wire수	2.5~3.5: 48 4.0~6.0: 64	64	2.5, 3.0 : - Outer 16 - Inner 36 3.5~5.5 : - Outer 16 - Inner 48	2.5~4.5: 48 5.0, 6.0: 52
Size(mm)	OD : 2.5~6.0 Length: 12~50	OD : 2.5~5.25 Length : 12~50	2.5~5.5 Length : 13~45	2.5~6.0 Length : 10~50
마이크로 카테터(inch)	2.5~3.5: 0.021 4.0~6.0: 0.027	0.027	2.5, 3.0 : 0.021 3.5~5.5 : 0.027	2.5~3.5 : 0.017 3.5~6.0 : 0.027
Surface modification	Phosphorylcholine	BioStealth™	X-technology	BlueXide
그 외 특징	44% thin PTFE sleeve	Petal	Dual layer Little delivery wire tip	Low profile

급여 기준

1. 직경 10 mm 이상의 비파열성 뇌동맥류
2. 직경 10 mm 미만의 비파열성 뇌동맥류
 - (1) 내경동맥 원위부의 수포성 뇌동맥류
 - (2) 방추형 뇌동맥류
 - (3) 척추동맥의 박리형 뇌동맥류
 - (4) 두개강내 내경동맥에 발생한, 인접한 다발성 뇌동맥류로서 직경의 합이 10 mm 이상인 경우

* 급여개수 : 1개

* 코일 병용: 직경 15 mm 이상의 뇌동맥류인 경우 최대 5개 인정

Expanded Off-Label Indications

1. Beyond to the circle of Willis
(distal, small, bifurcation)
2. Acutely ruptured aneurysms
3. Posterior circulation
4. Recurrent aneurysms
5. Carotid-cavernous fistula

FUTURE OF FD

Surface
modification

Low-profile

Easy opening &
Wall apposition

Visibility





SUMMARY

- FD is a safe and effective treatment modality for Large or complex intracranial aneurysms.
- Development of FD could be promising.

MEMO //////////////////////////////////////

Flow diverter: technique and complication

정 영 진
영남대병원







How to Prevention, Avoid, Minimize & Escape COMPLICATIONS of the **FLOW DIVERSION**

정영진

CCH, JH KIM

Neurosurgery, Stroke Center, YUMC, Daegu, S. Kore





Complications of the FD

1. Pre FD

1. Delivery Failure d/t unstable guiding system/ Proximal support
2. Delivery Failure d/t guiding system fracture

2. During FD

1. Not fully expand, Pipeline Distal end d/t PTFE sleeves
2. Not fully expand, FD d/t fibrin mesh ??
3. Stent migration/ displacement
4. Vessel perforation or injury

3. After FD

1. Hemorrhagic cx.
2. Ischemic cx. : Perforator injury, TEC, Occlusion
3. Recurred

4. Unexpected

Complications of the FD

1. Pre FD

1. Delivery Failure d/t unstable guiding system/
Proximal support
: Multiple Axis (8Fr sheath) (Sofia 5Fr/ 27 MC, beyond the lesion)
2. Delivery Failure d/t guiding system fracture
: Axis offset catheter/ MC exchange

Delivery Failure d/t guiding system fracture
: Axis offset catheter/ MC exchange



Delivery Failure d/t

Unstable Guiding system/ Proximal support

: Multiple Axis (8Fr sheath) (Sofia 5Fr/ 27 MC, beyond the lesion)




Complications of the FD

2. During FD

1. Not fully expand, Pipeline Distal end d/t PTFE sleeves
: Ex-vivo release the PTFE sleeves (Not necessary after PED vantage, Derivo)
2. Not fully expand, FD d/t fibrin mesh ??
: Reasonably quick delivery (minimal push & pull)
3. Stent migration/ displacement
: proper anchoring both distal end (2-3mm??)
4. Vessel perforation or injury
: caution the distal tip

Not fully expand, Pipeline Distal end d/t PTFE sleeves

: Ex-vivo release the PTFE sleeves (Not necessary after PED vantage, Derivo)



<https://neuroangio.org/pipeline-device/pipeline-classic/>


Not fully expand, FD d/t fibrin mesh ??

: Reasonably quick delivery (minimal push & pull)



Stent migration/ displacement
: **proper anchoring (2~3mm??)**

Vessel perforation or injury
: **caution the distal tip**



<https://neuroangio.org/pipeline-device/pipeline-classic/>

Complications of the FD

3. After FD

1. Hemorrhagic cx.
: Jet flow, Unstable an. (wall enhanced, thrombosed)
2. Ischemic cx. : Perforator injury, TEC, Occlusion
: Medication, Wall apposition (Balloon angioplasty),
3. Recurred
: Additional FD, Proximal occlusion c/w bypass


Hemorrhagic cx.

: Jet flow, Unstable an. (wall enhanced, thrombosed)



: Multiple FD, Steroid, ABR







**Case 1,
51 YOF, UIA, HA
2020.12.23**




First, Coils






Then, PED





51 YOF, UIA, HA 2020.12.23, #POD 0d



51 YOF, UIA, HA 2020.12.24, #POD 1day








Case 2

23561899, 81 YOF, UIA



FD (Surpass) & Trapping




Post OP, FD (+)



Post OP, FD (+)
& Rt VA Trap (+)

#POD 5, After Bleeds




Ischemic cx. : Perforator injury, TEC, Occlusion
: Medication, Wall apposition (Balloon angioplasty)






Final



F/U



Review of Previous FD



Rt





Lt


Recurred

- : Mass effects,
- : Additional FD, Proximal occlusion c/w bypass

Case 4
70 YOF, 19566839
Overlapping PED



Post OP




INITIAL




OTL...


*Aggravation, Gait disturbance




1 WEEK



4 WEEKS




4 MONTHS





12 MONTHS



12 Months, F/U



2nd PED, (#POD 12M)





BNET 3rd : Advanced Treatment Strategies for aneurysm (Flow diverter & disruptor)




How to Reduce,


30017445 73 YOF UIA, H/A




2024.04.02.




Working view (04.02)









Working view (04.02)






BNET 3rd : Advanced Treatment Strategies for aneurysm (Flow diverter & disruptor)





BNET 3rd : Advanced Treatment Strategies for aneurysm (Flow diverter & disruptor)



2nd PED, Final Angiogram (삭감???)







Take home message



Flow disruptor

정 준 호

연세대 강남세브란스병원



BNET-3. May 11, 2024.

Flow-Disruptor

Advanced Treatment Strategy for IAs

Joonho Chung, M.D., Ph.D.

Associate Professor

Department of Neurosurgery


Gangnam Severance Hospital

Yonsei University College of Medicine




Prevention of Rebleeding from aneurysm

Clipping (1937)



Coiling (1991)



WHY ?

한 개인의 철학은 자세를 결정하고,
자세는 행동을 결정하며,
행동에 따라 결과가 결정되므로
결국 자세는 인생을 결정한다.

Innate Talent & Acquired Skills

IF YOU'RE NOT
WILLING TO PUT
IN THE EFFORT,
DON'T EXPECT
ANYTHING
IN RETURN.

Simple Short Safe

Endovascular Devices Be Aware with Complete Understanding

Evidences in EVT (Intracranial aneurysms)

ARTICLES

Articles

Lancet 2002; **360**: 1267-74

International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical
clipping
rupture

International

At 1 year,
Survival free of disability
Coiling > Clipping

Evidences in EVT (Intracranial aneurysms)

International subarachnoid aneurysm trial (ISAT) of
neurosurgical clipping versus endovascular coiling in 2143
patients with ruptured intracranial aneurysms: a randomised

Lancet 2005;366:809-17

**At 1 year,
Dead or Dependent**

Coiling 23.5%

Clipping 30.9%

**Absolute risk
reduction 7.4%**
(P = 0.0001)

izures,

International Subarachnoid

Evidences in EVT (Intracranial aneurysms)

Risk of recurrent subarachnoid haemorrhage, death, or
dependence and standardised mortality ratios after clipping
or coiling of an intracranial aneurysm in the International
Subarachnoid Aneurysm Trial (ISAT): long-term follow-up

Lancet 2009;8:427-33

Andrew J Moly

**At 5 year, Risk of death
Significantly Lower
in Coiling Group**
(RR = 0.77; p = 0.03)

Evidences in EVT (Intracranial aneurysms)

AHA/ASA Guideline

Stroke 2012;43:1711-37

Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage

A Guideline for Healthcare Professionals From the American Heart
Association/American Stroke Association


Surgical and Endovascular Methods of Treatment
of Ruptured Cerebral Aneurysms:
Recommendations

1. Surgical clipping or endovascular coiling of the rup-

Endovascular Treatment $\geq$ Microsurgery

4. For patients with ruptured aneurysms judged to be technically amenable to both endovascular coiling and neurosurgical clipping, endovascular coiling should be considered (Class I; Level of Evidence B). (Revised recommendation from previous guidelines)

Neurointervention 2017; 12: 77-82
<https://doi.org/10.5469/neuroint.2017.12.2.77>
ISSN (Print): 2093-9043 ISSN (Online): 2233-6273



EVIDENCES

Ruptured Aneurysm

The durability of endovascular coiling versus neurosurgical clipping of ruptured cerebral aneurysms: 18 year follow-up of the UK cohort of the International Subarachnoid Aneurysm Trial (ISAT)




Figure 2: Kaplan-Meier plot of cumulative mortality. Patients observed for 10-18.5 years in 22 UK centres.




Figure 1: Kaplan-Meier plot of cumulative risk of rebleeding from target (treated) aneurysm later than 1 year after subarachnoid haemorrhage



Interpretation Although rates of increased dependency alone did not differ between groups, the probability of death or dependency was significantly greater in the neurosurgical group than in the endovascular group. Rebleeding was more likely after endovascular coiling than after neurosurgical clipping, but the risk was small and the probability of disability-free survival was significantly greater in the endovascular group than in the neurosurgical group at 10 years.

Neurovascular Research Unit,
Nuffield Department of Surgical
Sciences, University of Oxford,
Oxford OX3 9DU, UK
andy.molyneux@nds.ox.ac.uk

Intracranial Arteries....

1. Lack of Adventitia
2. Lack of Supportive Tissue
3. Very Tortuous
4. Importance of Perforators

BNET 3rd : Advanced Treatment Strategies for aneurysm (Flow diverter & disruptor)



Limitations

- 1) Giant aneurysm
- 2) ICA blister aneurysms
- 3) Recurrent aneurysm after EVT
- 4) Technical difficulties
 - Complex shape
 - Very small aneurysm
 - Branch incorporated
 - Fusiform aneurysm

Endovascular Devices


**Be Aware with
Complete
Understanding**




Mechanism of Action



MicroBraid™ Technology is designed to seal the neck and protect the dome¹:

- ~60% metal coverage at the neck and the dome of the aneurysm provides two layers of flow disruption
- Proximal recess limits vessel encroachment
- Nitinol surface provides scaffold for endothelialization around the aneurysm neck, sidewalls, and dome



Canine explant 2 months after treatment. Marker recess is filled with dense fibrous tissue²





Joonho Chung, M.D., Ph.D., Republic of KOREA
Joonho Chung, M.D., Ph.D., Republic of KOREA

보험 급여 기준


급여가격	WEB 10,579,770원* (선별급여 공단 50%/본인부담 50%)
	*심평원 환율기준 1단계로 적용된 금액
세부 인정 기준	가.급여대상:아래의 조건을 모두 충족한 뇌동맥류: 1) 뇌동맥류 위치 - 가)중대뇌동맥 분지(MCA bifurcation) - 나)내경동맥 말단(ICA terminus) - 다)전교통동맥 복합체(AComm complex)또는 뇌저동맥(Basilar Artery)첨부(Apex) 2) 뇌동맥류 모양 : 낭상동맥류(Saccular aneurysm) 3) 뇌동맥류 크기 : 직경3~10mm이고,경부4mm또는Dome-to-neck ratio 1~2인 경우 나. 급여개수: 1개 다.뇌동맥류 색전술용 Micro Coil 및 STENT의 병용사용이 불가피하게 필요한 경우,의사소견서 및 진료기록부 등 관련 자료를 첨부하여야 하며 제출된 관련 자료를 참조하여 사례별로 인정 <u>Contradictions</u> The WEB™ Aneurysm Embolization System is contraindicated for patients with known bacterial infection that may interfere with or negatively affect the implantation procedure and patients with known hypersensitivity to nickel For complete indications, contraindications, potential complications, warnings, precautions, and instructions, see instructions for use (IFU provided in the device).

Joonho Chung, M.D., Ph.D., Republic of KOREA
Joonho Chung, M.D., Ph.D., Republic of KOREA

Single Layer

Single Layer Sphere

Portfolio Overview	
Shapes	- Single Layer (SL) - Single Layer Sphere (SLS)
Sizes	- Diameter: 3 – 11mm - Height: 2 – 9mm
Implant Construction	
Metallic Components	- Pt-Ir Marker Bands - Pt-Ir Coupler - Nitinol and Nitinol-DFT wire
Non-Metal Components	- PET Tether - Epoxy
Number of Wires	3 – 7mm (17 system): 72-108 8-11mm (27/33 system): 180 – 216
Wire Sizes	0.00075” – 0.00125”
% Metal at Neck	59% – 62%



Joongho Chung, M.D., Ph.D., Republic of KOREA

VIA™ Microcatheter—Features & Benefits

Designed for optimal delivery, deployment, and retrieval of braided devices like the WEB® Device

- **Smooth Device Delivery**
Flat braid & coil design with lubricious PTFE liner maximizes lumen ID, providing smooth, low friction device delivery
- **Controlled Device Deployment**
Gradual shaft transitions and hybrid braid/coil design provide optimal catheter support for precise and uniform device deployment
- **Reliable Device Retrieval**
Balanced shaft transitions and robust column strength minimize tip movement, providing reliable device retrieval

MicroVention
TERUMO

Joongho Chung, M.D., Ph.D., Republic of KOREA

This section features a detailed image of a VIA™ Microcatheter, showing its flexible, braided design. To the right of the image, a list of features and benefits is provided, highlighting the catheter's design for optimal delivery, deployment, and retrieval of braided devices like the WEB® Device. The text describes the smooth device delivery, controlled device deployment, and reliable device retrieval capabilities. The MicroVention TERUMO logo is located at the bottom right of the section.

BNET 3rd : Advanced Treatment Strategies for aneurysm (Flow diverter & disruptor)

Joonho Chung, M.D., Ph.D., Republic of KOREA

Access Devices Compatibility			
WEB® SL/SLS Device Width (mm)	VIA® Microcatheter (Delivery Catheter)	Intracranial Support Catheter	Long Sheath
3 – 7	VIA® 17 ID: 0.0175" / 1.3F / 0.44 mm Distal OD: 2.3F / 0.029" / 0.074 mm vs. 1.7F Headway 17 Proximal OD: 2.5F / 0.032" / 0.81 mm Length: 154 cm	SOFIA® 5F or 6F 115cm	6F: 80 / 90 cm long
8 – 9	VIA® 27 ID: 0.027" / 2.1F / 0.69 mm Distal OD: 3.0F / 0.039" / 0.99 mm vs. 2.6F Headway 27 Proximal OD: 3.2 F / 0.042" / 1.07 mm Length: 154 cm	SOFIA 6F 115cm	6F: 80 / 90 cm long
10 – 11	VIA® 33 ID: 0.033" / 2.5F / 0.84 mm Distal OD: 3.4F / 0.045" / 1.14 mm Proximal OD: 3.8F / 0.050" / 1.27 mm Length: 133 cm	SOFIA® 6F 115cm	6F: 80 / 90 cm long

Joonho Chung, M.D., Ph.D., Republic of KOREA

Joonho Chung, M.D., Ph.D., Republic of KOREA

WEB™ Device Selection—3 Step Process

STEP 1: Measure Aneurysm

Measure the size (*Width, Height, and Neck*) of the aneurysm in two orthogonal projections.

STEP 2: Select Shape

Select the appropriate WEB™ device shape: SL (*Single Layer*) or SLS (*Single Layer Spherical*)

STEP 3: Select WEB Size


Refer to the corresponding WEB™ Device Selection Table to determine the correct WEB™ device size

Joonho Chung, M.D., Ph.D., Republic of KOREA


76

STEP 1: Measure


- Measure the Aneurysm in Two Orthogonal Projections



Measure the:
 ■ NECK
 ■ WIDTH
 ■ HEIGHT



Measure the:
 ■ NECK
 ■ WIDTH
 ■ HEIGHT



Exclude blebs and secondary lobes.

Since the WEB™ device does not need to conform all the way to the rounded or narrowed dome, there is no need to measure the height to the top of the aneurysm.



STEP 2: Select

- Choose WEB™ SL (Single Layer) or WEB™ SLS (Single Layer Spherical) Device



Measuring and identifying the neck type of the aneurysm will help to determine the best WEB™ device shape to better seal the aneurysm neck and protect daughter vessels.

WEB® SL (Single Layer)



The WEB™ SL implant is the device of choice in most wide-neck bifurcation aneurysms.

WEB® SLS (Single Layer Spherical)



The WEB™ SLS implant is the device of choice in most narrowed-neck bifurcation aneurysms.

If the WEB™ SLS device is selected, but the aneurysm height is shorter than the suggested device, then the WEB™ SL device is recommended.



Joonho Chung, M.D., Ph.D., Republic of KOREA

WEB™ SL Device Selection Table

SMALLEST ANEURYSM HEIGHT (mm)	9.5-10.4											SL 11x9
	8.5-9.4										SL 10x8	SL 11x8
	7.5-8.4									SL 9x7	SL 10x7	SL 11x7
	6.5-7.4								SL 8x6	SL 9x6	SL 10x6	SL 11x6
	5.5-6.4							SL 7x5	SL 8x5	SL 9x5	SL 10x5	
	4.5-5.4						SL 6x4	SL 7x4	SL 8x4	SL 9x4		
	3.5-4.4			SL 4x3	SL 4.5x3	SL 5x3	SL 6x3	SL 7x3	SL 8x3			
	2.5-3.4	SL 3x2	SL 3.5x2	SL 4x2	SL 4.5x2	SL 5x2	SL 6x2	SL 7x2				
		2.0-2.6	2.7-3.1	3.2-3.6	3.7-4.1	4.2-4.6	4.7-5.5	5.6-6.5	6.6-7.4	7.5-8.3	8.4-9.2	9.3-10.0
AVERAGE ANEURYSM WIDTH (mm)												
DELIVERY CATHETER												
VIA 17VIA 27VIA 33												

Joonho Chung, M.D., Ph.D., Republic of KOREA

Joonho Chung, M.D., Ph.D., Republic of KOREA

WEB™ SLS Device Selection Table


SMALLEST ANEURYSM HEIGHT (mm)	10.6								SLS 11
	9.6							SLS 10	
	8.6						SLS 9		
	7.6					SLS 8			
	6.6				SLS 7				
	5.6			SLS 6					
	4.6		SLS 5						
	3.6	SLS 4							
		3-3.7	3.8-4.6	4.7-5.5	5.6-6.5	6.6-7.4	7.5-8.3	8.4-9.2	9.3-10.0
AVERAGE ANEURYSM WIDTH (mm)									
DELIVERY CATHETER									
VIA 17VIA 27VIA 33									

Joonho Chung, M.D., Ph.D., Republic of KOREA

Choose WEB™ SL Device using the WEB™ SL Device Selection Table

A. Width Determination

Determine the average Aneurysm Width from 2 orthogonal projections

P1

6.4 mm

P2


6.0 mm

6.2 mm
Average Width

$(6.4\text{ mm} + 6.0\text{ mm})/2 = 6.2\text{ mm}$

B. Height Determination

Take the smallest Aneurysm Height from 2 orthogonal projections

P1

5.1 mm

P2

6.4 mm

5.1 mm
Smallest Height

C. Device Selection

Smallest Aneurysm Height (mm)	2.0-2.6	2.7-3.1	3.2-3.6	3.7-4.1	4.2-4.6	4.7-5.5	5.6-6.5	6.6-7.4	7.5-8.3	8.4-9.2	9.3-10.0
9.5-10.4											SL 11x9
8.5-9.4											SL 10x8
7.5-8.4										SL 9x7	SL 10x7
6.5-7.4									SL 8x6	SL 9x6	SL 10x6
5.5-6.4								SL 7x5	SL 8x5	SL 9x5	SL 10x5
4.5-5.4							SL 6x4	SL 7x4	SL 8x4	SL 9x4	
3.5-4.4			SL 4x3	SL 4.5x3	SL 5x3	SL 6x3	SL 7x3	SL 8x3			
2.5-3.4	SL 3x2	SL 3.5x2	SL 4x2	SL 4.5x2	SL 5x2						
2.0-2.6											

AVERAGE ANEURYSM WIDTH (mm)

VIA 17 6.2 VIA 27 VIA 33

 **WEB™ SL 7x4**



Size Selection Impacts Device Stability


WEB™ SL 8x6

→


Tube diameter: 8 mm

Inadequate Wall Apposition:
The WEB™ device may collapse under pressure.
UNDERSIZED DEVICE.




WEB™ SL 9x5

→


Tube diameter: 8 mm

Good Wall Apposition:
The WEB™ device resists compression, it is stable and durable.
CORRECTLY SIZED DEVICE.





Joonho Chung, M.D., Ph.D., Republic of KOREA

VIA® Microcatheter Positioning


Reposition the tip of the microcatheter so that it sits just at the neck of the aneurysm.

Do not insert the microcatheter completely inside the aneurysm.

⚠ The VIA® microcatheter extends an additional 1mm beyond the marker tip.

Carefully advance the device until the distal end of the device reaches the last marker on the microcatheter.

Maintain visualization of the microcatheter tip during device delivery.




Joonho Chung, M.D., Ph.D., Republic of KOREA

Joonho Chung, M.D., Ph.D., Republic of KOREA

VIA® Microcatheter Positioning


Neuroradiology (2008) 50:423–427





Joonho Chung, M.D., Ph.D., Republic of KOREA

Deployment Considerations: Off-Center Catheter

- An off-center catheter position can be self-correcting upon deployment






WEB[®] Device Deployment - Sprout

The diagram illustrates the deployment of the WEB Sprout device. It shows a catheter with a device at the tip, labeled 'B'. The device is shown in a partially deployed state, with a label indicating '~1/2 of Fully Deployed Diameter'. The device is divided into two sections: a longer section labeled '2/3' and a shorter section labeled '1/3'. Below the diagram are three images: 'SL' (Side View), 'SLS' (Side View with Scale), and a 3D model of the device deployed in a vessel. The 'SL' and 'SLS' images show the device in a catheter, with the 'SLS' image providing a scale. The 3D model shows the device deployed in a vessel, with a label indicating 'Distal Implant Marker'. The MicroVention TERUMO logo is at the bottom right.

WEB[®] Device Deployment - Flower

The diagram illustrates the deployment of the WEB Flower device. It shows a catheter with a device at the tip, labeled 'C'. The device is shown in a partially deployed state, with a label indicating '~4/5 of Fully Deployed Diameter'. The device is divided into two sections: a longer section labeled '1/3' and a shorter section labeled '2/3'. Below the diagram are three images: 'SL' (Side View), 'SLS' (Side View with Scale), and a 3D model of the device deployed in a vessel. The 'SL' and 'SLS' images show the device in a catheter, with the 'SLS' image providing a scale. The 3D model shows the device deployed in a vessel, with labels indicating 'Distal Recess' and 'Distal Implant Marker'. The MicroVention TERUMO logo is at the bottom right.

WEB® Device Fully deployed




MicroVention
TERUMO

Post-Deployment Assessment: **NEUTRAL SYSTEM**

- Verify that the distal portion of the delivery device is not under tension or compression prior to detachment.

7 SLS Device



Compression
Too much load on the
device pusher wire


Neutral

Tension
Too much tension on
device pusher wire

MicroVention
TERUMO


Post-Deployment Assessment: **POSITION**

- The device should be placed to seal the aneurysm neck and protect daughter vessels
- To achieve optimum alignment of the WEB® Device, the device should be placed with **minimal angulation relative to the axis of the aneurysm**
- Off-axis deployment may result in a poor seal of the neck and persistent neck remnant



MicroVention
TERUMO

Unloading before detachment



MicroVention
TERUMO

Sticky Detachment



1. Carefully bring the VIA microcatheter over the detachment zone to the base of the WEB device to brace against the WEB device. In some instances, this manipulation is sufficient to completely detach the WEB device.
2. Push the WEB device very gently forward with pusher wire. This manipulation can sever the tether if there is a true sticky detachment
3. Bring the pusher wire very slowly into the VIA microcatheter
4. Carefully retract the VIA microcatheter to ensure that the proximal marker of the WEB device does not get caught in the lip of the VIA microcatheter. This is more likely when there is a notable entry angle into the aneurysm.



WEBable ?

WEBable ?

1. Shape


2. Size

3. Axis

Joonho Chung, M.D., Ph.D., Republic of KOREA

Joonho Chung, M.D., Ph.D., Republic of KOREA


1. Shape




Joonho Chung, M.D., Ph.D., Republic of KOREA


Joonho Chung, M.D., Ph.D., Republic of KOREA

BNET 3rd : Advanced Treatment Strategies for aneurysm (Flow diverter & disruptor)



BNET 3rd : Advanced Treatment Strategies for aneurysm (Flow diverter & disruptor)








1. Shape






BNET 3rd : Advanced Treatment Strategies for aneurysm (Flow diverter & disruptor)







1. Shape



BNET 3rd : Advanced Treatment Strategies for aneurysm (Flow diverter & disruptor)





1. Shape



Joonho Chung, M.D., Ph.D., Republic of KOREA

Joonho Chung, M.D., Ph.D., Republic of KOREA

1. Shape




Joonho Chung, M.D., Ph.D., Republic of KOREA

Joonho Chung, M.D., Ph.D., Republic of KOREA


Joonho Chung, M.D., Ph.D., Republic of KOREA

1. Shape



Joonho Chung, M.D., Ph.D., Republic of KOREA

Joonho Chung, M.D., Ph.D., Republic of KOREA




Joonho Chung, M.D., Ph.D., Republic of KOREA



BNET 3rd : Advanced Treatment Strategies for aneurysm (Flow diverter & disruptor)





BNET 3rd : Advanced Treatment Strategies for aneurysm (Flow diverter & disruptor)





BNET 3rd : Advanced Treatment Strategies for aneurysm (Flow diverter & disruptor)



BNET 3rd : Advanced Treatment Strategies for aneurysm (Flow diverter & disruptor)





Clinical Neuroradiology
<https://doi.org/10.1007/s00062-024-01405-3>

CORRESPONDENCE



Endovascular Treatment of a Wide-necked Bilobulated Bifurcation Aneurysm using the Woven EndoBridge (WEB) Device

A Kissing WEB Technique


Junhyung Kim¹ · Sang Kyu Park¹ · Joonho Chung¹

Received: 9 January 2024 / Accepted: 13 March 2024
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2024

2. Size


Device size
3-11 mm

BNET 3rd : Advanced Treatment Strategies for aneurysm (Flow diverter & disruptor)




Joonho Chung, M.D., Ph.D., Republic of KOREA

2. Size





Joonho Chung, M.D., Ph.D., Republic of KOREA


Joonho Chung, M.D., Ph.D., Republic of KOREA




Joonho Chung, M.D., Ph.D., Republic of KOREA




2. Size






2. Size





Joonho Chung, M.D., Ph.D., Republic of KOREA

3. Axis (angioarchitecture)




Courtesy of KY Park

Joonho Chung, M.D., Ph.D., Republic of KOREA


Joonho Chung, M.D., Ph.D., Republic of KOREA

3. Axis (angioarchitecture)







Joonho Chung, M.D., Ph.D., Republic of KOREA

BNET 3rd : Advanced Treatment Strategies for aneurysm (Flow diverter & disruptor)
















BNET 3rd : Advanced Treatment Strategies for aneurysm (Flow diverter & disruptor)





BNET 3rd : Advanced Treatment Strategies for aneurysm (Flow diverter & disruptor)




BNET 3rd : Advanced Treatment Strategies for aneurysm (Flow diverter & disruptor)

Joonho Chung, M.D., Ph.D., Republic of KOREA

	WEB-IT US IDE Study ¹	European GCP Studies		CLARYS Ruptured Aneurysm Study ⁴
		(1 year) ² WEBCAST, WEBCAST-2, and FROBS	(5 Year) ³ WEBCAST, WEBCAST-2	
Number of patients	150	168	100	60
Number of aneurysms	150	169	95	60
▪ Basilar Apex	39.3% (59/150)	17.8% (30/169)	17.9% (17/95)	11.7% (7/60)
▪ ICA Terminus	4.0% (6/150)	10.1% (17/169)	9.5% (9/95)	1.7% (1/60)
▪ MCA Bifurcation	30.0% (45/150)	50.9% (86/169)	51.6% (49/95)	38.3% (23/60)
▪ Acomm Complex	26.7% (40/150)	21.3% (36/169)	21.1% (20/95)	43.3% (26/60)
▪ Other	0	0	0	5.0% (3/60)
Average aneurysm diameter	6.4 mm	7.6 mm	7.3 ± 2.6mm	6.6 mm
Ruptured aneurysms	6.0% (9/150)	8.3% (14/169)	7.4% (7/95)	100%
Devices/Procedures Evaluated	WEB DL (12.8%) WEB SL/SLS (87.2%)	WEB DL (47.9%) WEB SL/SLS (52.1%)	WEB DL (46.3%) WEB SL/SLS (53.7%)	WEB SL/SLS

Joonho Chung, M.D., Ph.D., Republic of KOREA

Joonho Chung, M.D., Ph.D., Republic of KOREA



Joonho Chung, M.D., Ph.D., Republic of KOREA

Angiographic Follow-Up				
	European GCP Studies			
	WEB-IT US IDE ^{1,*}	(2 Year) ² WEBCAST, WEBCAST-2, and FROBS	(5 Year) ³ WEBCAST, WEBCAST-2	CLARYS Ruptured Aneurysm Study ⁴
Angiographic Follow-up	1 year	2 years	5 years	1 year
Complete Occlusion	53.8% (77/143)	51.2% (62/121)	51.6% (49/95)	41.3% (19/46)
Neck Remnant	30.8% (44/143)	29.8% (36/121)	26.3% (25/95)	45.7% (21/46)
Aneurysm Remnant	10.5% (15/143)	19.0% (23/121)	22.1% (21/95)	13.0% (6/46)
Adequate Occlusion	84.6% (121/143)	81.0% (98/121)	77.9% (74/95)	87.0% (40/46)
Retreatment A B C	5.6% (8/143)	9.2% (14/152)	11.6% (11/95)	11.5% (6/52)

	European GCP Studies			
	WEB-IT US IDE Study ¹	(2 Year) ² WEBCAST, WEBCAST-2, and FROBS	(5 Year) ³ WEBCAST, WEBCAST-2	CLARYS Ruptured Aneurysm Study ⁴
Morbidity	1.4% (2/143)	1.4% (2/138)	1.0%*	9.6% (5/52)*
Mortality	0% (0/143)	0.7% (1/138)	7.0%*	3.8% (2/52)*
Re-Bleeding or Bleeding during follow-up period	0%	0%	0%	0%
Time Period	1 year	2 years	5 years	1 year

	WEB-IT US IDE Study ¹	European GCP Studies ²	CLARYS Ruptured Aneurysm Study ³
Technical Success	98.7% (148/150)	96.4% (163/169)	93.3% (56/60)
Adjunctive Devices Implanted	1.4% (2/148)	7.4% (12/163)	3.6% (2/56)
Fluoroscopy Time	30.2 ± 15.7 min	NR	27.0 ± 16.0 min
WEB Device Time*	20.9 ± 21.2 min	NR	NR
Total Procedure Time	NR	NR	75.3 ± 42.7 min

Joinho Chung, M.D., Ph.D., Republic of KOREA



Original research

Safety and effectiveness of the Woven EndoBridge (WEB) system for the treatment of wide necked bifurcation aneurysms: final 5 year results of the pivotal WEB Intra-saccular Therapy study (WEB-IT)

David Fiorella ¹, Andy Molyneux,² Alex Coon,³ Istvan Szikora ⁴, Isil Saatci ⁵, Feyyaz Baltacioglu,⁶ Mohammad A Aziz-Sultan,⁷ Daniel Hoit,⁸ Josser E Delgado Almandoz ⁹, Lucas Eljovich ¹⁰, H Saruhan Cekirge ^{11,12}, James Byrne,¹³ Joachim Klisch,¹⁴ Adam S Arthur ^{10,15}

ABSTRACT

Introduction The US Woven EndoBridge Intra-saccular Therapy (WEB-IT) study is a pivotal, prospective, single arm, investigational device exemption study to evaluate the safety and effectiveness of the WEB device for the treatment of wide neck bifurcation aneurysms (WNBAs). We present complete 5 year data for the cohort of 150 patients.

Methods 150 patients with WNBAs were enrolled at 21 US and six international centers. Imaging from the index procedure, 6 month, 1 year, 3 year, and 5 year follow-up were reviewed by a core laboratory. Adverse events were reviewed and adjudicated by a clinical events adjudicator.

Results 83 patients had 5 year follow-up imaging and 123 had clinical follow-up. No ruptured (0/9) or unruptured aneurysm (0/141) rebled or bled during follow-up. No new device or procedure related adverse events or serious adverse events were reported after 1 year. At 5 years, using the LOCF method, complete occlusion was observed in 58.1% and adequate occlusion in 87.2% of patients. For patients with both 1 year and 5 year occlusion statuses available, 76.8% (63/82) of aneurysms remained stable or improved with no retreatment. After 1 year, 18 aneurysms were retreated, 11 of which were adequately occluded at 1 year, and 15 of which were retreated in the absence of any deterioration in occlusion grade.

Conclusions Five year follow-up data from the WEB-IT study demonstrated that the WEB device was safe and effective when used in the treatment of WNBAs. Aneurysm occlusion rates achieved at 1 year follow-up were durable, with rates of progressive thrombosis far exceeding rates of recurrence over time.

Joinho Chung, M.D., Ph.D., Republic of KOREA

Joinho Chung, M.D., Ph.D., Republic of KOREA

0% Rebleeding Rate in Multiple Studies

	CLARYS ¹	Single Center Ruptured Aneurysm Series (van Rooij et al) ²	US Multicenter Ruptured Aneurysm Experience (Cortez et al) ³	WEB-IT US IDE ⁴	Cumulative WEB GCP Studies ⁵
GCP Study	✓			✓	✓
Ruptured Aneurysms	100% (60/60)	100% (100/100)	100% (94/94)	6.2% (9/143)	8.3% (14/169)
Aneurysms / Patients	60	100	94 / 91	143	169/168
Aneurysm Re-Rupture	0% (1 year)	0% (3 months)	0% (3 months)	0% (1 year)	0% (1 year)

1. Spelle, L., et al. (2021). "Clinical Assessment of WEB device in Ruptured aneurysms (CLARYS): results of 1-month and 1-year assessment of rebleeding protection and clinical safety in a multicenter study." J Neurointerv Surg.

2. van Rooij SBT, van Rooij WJ, Peluso JP, et al. WEB Treatment of Ruptured Intracranial Aneurysms: A Single-Center Cohort of 100 Patients. AJNR Am J Neuroradiol 2017;38:2282-7.

3. Cortez GM, Altare G, Montoya A, et al. Woven EndoBridge device for ruptured aneurysms: peroperative results of a US multicenter experience. J Neurointerv Surg 2021.

4. Arthur SA, Molyneux A, Coon AL, et al. The safety and effectiveness of the Woven EndoBridge (WEB) system for the treatment of wide-necked bifurcation aneurysms: final 12-month results of the pivotal WEB Intra-saccular Therapy (WEB-IT). J Neurointerv Surg 2019;11:924-930.

5. Pierot L, Moore J, Barroux K, et al. Safety and efficacy of aneurysm treatment with WEB in the cumulative population of three prospective, multicenter series. J Neurointerv Surg 2018 ; 10: 553-558.



Joinho Chung, M.D., Ph.D., Republic of KOREA

Ruptured Aneurysm Treatment

Safety and Efficacy of the Woven EndoBridge Device for Treatment of Ruptured Intracranial Aneurysms: A Systematic Review and Meta-analysis

MA, Essiyabi, G. Lanzino, and W. Brinjikji

ABSTRACT

BACKGROUND: The Woven EndoBridge device has been increasingly used to treat wide-neck aneurysms, particularly ruptured ones.

PURPOSE: Our aim was to investigate the safety and efficacy of the Woven EndoBridge device in the treatment of ruptured intracranial aneurysms.

DATA SOURCES: All studies evaluating the outcomes of Woven EndoBridge device use in the treatment of ruptured intracranial aneurysms from inception through 2020 were searched on Ovid Evidence-Based Medicine Reviews, EMBASE, MEDLINE, Scopus, and the Web of Science Core Collection.

STUDY SELECTION: Eighteen studies encompassing 487 patients with 496 ruptured aneurysms treated with the Woven EndoBridge device were included.

ORIGINAL RESEARCH
INTERVENTIONAL

Ruptured Aneurysm Meta-Analysis

Essiyabi et al. 2021.

- 487 patients | 496 aneurysms
- 1.1% Rebleeding after procedure
 - in-line with coiling alone and balloon-assisted coiling
- DAPT not required
- 2.1% procedure-related mortality
- 3.2% overall clinical complication rate related to WEB
- 87.3% adequate occlusion
- 5.1% retreatment



Opinion

- **Feasibility: Excellent**
- **Efficacy: Good, but not easy**
- **Safety: Good, but not easy**
- **Durability: Good** (longer term results ?)
- **Comparative Clinical Trials**


**Simple
Short
Safe**

*Precision
Medicine*



**Simple
Short
Safe**

**Selection
Selection
Selection**



MEMO //////////////////////////////////////

MEMO //////////////////////////////////////

Basic NeuroEndovascular Training Course 3 (BNET Course)

인 쇄: 2024년 5월 11일

발 행: 2024년 5월 08일

발행처: 대한뇌혈관내치료의학회

(06631) 서울 서초구 서초대로 350 (서초동, 동아빌라트2타운) 407호

Tel_02-2279-9560 / E-mail_kones@konesonline.or.kr

<https://www.konesonline.or.kr>

회 장: 권순찬

부회장: 박석규



총 무: 하성곤

수련교육: 김영우, 박중철

WEB™

Aneurysm Embolization System

**LEADING THE WAY IN
INTRASACULAR
FLOW DISRUPTION**



LVIS™ EVO™

Intraluminal Support Device

**SEEING IS
BELIEVING**



Indications for Use:

The LVIS EVO device is intended for use with embolic coils for the treatment of intracranial neurovascular diseases.

The WEB Aneurysm Embolization System is intended for the endovascular embolization of ruptured and unruptured intracranial aneurysms and other neurovascular abnormalities such as arteriovenous fistulae (AVF). The WEB Aneurysm Embolization System is also intended for vascular occlusion of blood vessels within the neurovascular system to permanently obstruct blood flow to an aneurysm or other vascular malformation. The device should only be used by physicians who have undergone training in all aspects of the WEB Aneurysm Embolization System procedures as prescribed by Sequent Medical, Inc.

The VIA™ Catheter is intended for the introduction of non-liquid interventional devices (such as coils/stents/flow diverters) and infusion of diagnostic (such as contrast media) or non-liquid therapeutic agents into the neuro, peripheral, and coronary vasculature.

For Healthcare Professional Intended Use Only. Please refer to IFU for the full list of risks, contraindications, warnings, and precautions.

RX Only: Federal law restricts this device to sale by or on the order of a physician.

Class III - CE0297

Please note: not all products displayed are available for sale or distribution in all regions

MICROVENTION, EVO and LVIS are registered trademarks of MicroVention, Inc. in the United States and other jurisdictions. WEB and VIA are registered trademarks of Sequent Medical, Inc. © 2022 MicroVention, Inc.